Literature DB >> 9493528

Under reporting of sleepiness and driving impairment in patients with sleep apnoea/hypopnoea syndrome.

H M Engleman1, W S Hirst, N J Douglas.   

Abstract

Under reporting of symptoms by patients with sleep apnoea/hypopnoea syndrome (SAHS) has been reported anecdotally, but investigation of the prevalence or determinants of this is limited. To assess this, repeated ratings in 99 patients with sleep apnoea/hypopnoea syndrome of pre-treatment Epworth sleepiness score, unintended napping, driving impairment and mood were obtained, first at presentation and then after treatment with continuous positive airway pressure (CPAP) therapy of median 22 (range 2-70) weeks duration. Median Epworth score for pre-treatment sleepiness rose from 12 (range 0-24) initially to 14 (range 5-24) retrospectively (P<0.0001). More patients initially under-rated Epworth score (67%) than over-rated (29%; P<0.001). 'False negative' cases with an initially 'normal' (< or = 10) and retrospectively 'sleepy' (> or = 11) Epworth score comprised 24% of all patients and 62% of initially 'normal' scorers. Unintended napping behaviour also was rated as significantly more severe on retrospective assessment (P<0.001). Driving impairment due to sleepiness was initially reported by 23% of all drivers and retrospectively by 37% (P=0.01), with 25% of initial deniers retrospectively admitting compromised driving ability before continuous positive airway pressure. No polysomnographic predictors of symptom under reporting were found (P>0.1). These results suggest a high prevalence of symptom minimization before treatment in patients with sleep apnoea/hypopnoea syndrome.

Entities:  

Mesh:

Year:  1997        PMID: 9493528     DOI: 10.1111/j.1365-2869.1997.00272.x

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  20 in total

Review 1.  Sleep . 3: Clinical presentation and diagnosis of the obstructive sleep apnoea hypopnoea syndrome.

Authors:  D Schlosshan; M W Elliott
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

2.  CONTEXTUALIZING NATURALISTIC DRIVING DATA IN A RURAL STATE AMONG DRIVERS WITH AND WITHOUT OBSTRUCTIVE SLEEP APNEA.

Authors:  Jeffrey D Dawson; Elizabeth Bair; Nazan Askan; Kelly Sewell; Jon Tippin; Matthew Rizzo
Journal:  Proc Int Driv Symp Hum Factors Driv Assess Train Veh Des       Date:  2017-06

3.  Driver Performance in the Moments Surrounding a Microsleep.

Authors:  Linda Ng Boyle; Jon Tippin; Amit Paul; Matthew Rizzo
Journal:  Transp Res Part F Traffic Psychol Behav       Date:  2008-03-01

4.  Who needs sleep apnea treatment for safety critical tasks--are we there yet?

Authors:  Mark E Howard; Melinda L Jackson; Mark Stevenson
Journal:  Sleep       Date:  2015-03-01       Impact factor: 5.849

5.  Obstructive sleep apnoea/hypopnoea syndrome and hypertension.

Authors:  Mohammed A Al-Abri; Khamis M Al-Hashmi
Journal:  Sultan Qaboos Univ Med J       Date:  2008-11

6.  USING FEEDBACK FROM NATURALISTIC DRIVING TO IMPROVE TREATMENT ADHERENCE IN DRIVERS WITH OBSTRUCTIVE SLEEP APNEA.

Authors:  J Tucker Krone; Jeffrey D Dawson; Steven W Anderson; Nazan S Aksan; Jon Tippin; Matthew Rizzo
Journal:  Proc Int Driv Symp Hum Factors Driv Assess Train Veh Des       Date:  2013

Review 7.  Sleep. 5: Driving and automobile crashes in patients with obstructive sleep apnoea/hypopnoea syndrome.

Authors:  C F P George
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

8.  FEEDBACK FROM NATURALISTIC DRIVING IMPROVES TREATMENT COMPLIANCE IN DRIVERS WITH OBSTRUCTIVE SLEEP APNEA.

Authors:  Jeffrey D Dawson; Lixi Yu; Nazan S Aksan; Jon Tippin; Matthew Rizzo; Steven W Anderson
Journal:  Proc Int Driv Symp Hum Factors Driv Assess Train Veh Des       Date:  2015-06

9.  Visual vigilance in drivers with obstructive sleep apnea.

Authors:  Jon Tippin; JonDavid Sparks; Matthew Rizzo
Journal:  J Psychosom Res       Date:  2009-05-19       Impact factor: 3.006

10.  Minimal hepatic encephalopathy matters in daily life.

Authors:  Jasmohan S Bajaj
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.